MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Open Access
- 31 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 13 (1), 1-18
- https://doi.org/10.1186/s13045-020-0844-0
Abstract
PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib response, there are still evident limitations in the present approaches. Therefore, we aim to investigate more accurate approaches to predict Olaparib sensitivity and effective synergistic treatment strategies. We probed two databases (TCGA and Qilu Hospital) in order to quest novel miRNAs associated with platinum-sensitivity or HR-related genes. Cellular experiments in vitro or in vivo and PDX models were utilized to validate their role in tumor suppression and Olaparib sensitizing. Furthermore, HR gene mutation was analyzed through WES to explore the relation between HR gene mutation and Olaparib response. High miR-509-3 expression indicated better response to platinum and longer progression-free and overall survival in two independent ovarian cancer patient cohorts (high vs. low miR-509-3 expression; PFS: TCGA P < 0.05, Qilu P < 0.05; OS: TCGA P < 0.05, Qilu P < 0.01). MiR-509-3 could impair the proliferation, migration, and invasion ability but enhance the sensitivity to Olaparib of ovarian cancer cell in vitro and in vivo by directly targeting HMGA2 and RAD51. In two PDX cases (PDX1 and PDX9), miR-509-3 could significantly increase the sensitivity to Olaparib along with the decrease of RAD51 positive rate (mean tumor weight NC + Olaparib vs. miR-509 + Olaparib; PDX1 P < 0.05, PDX9 P < 0.05). Additionally, in PDX8, miR-509-3 treatment dramatically reversed the Olaparib insensitivity (P < 0.05) by downregulating RAD51 expression. RAD51 functional detection revealed that all Olaparib sensitive cases exhibited low RAD51 positive rate (lesser than 50%) in treated groups. Furthermore, among the four HR gene mutation patients, three harbored HR core gene mutation and were sensitive to Olaparib while the remaining one with non-HR core gene mutation did not respond well to Olaparib. MiR-509-3 can sensitize ovarian cancer cells to Olaparib by impeding HR, which makes it a potential target in PARPi synergistic treatment. HR core gene analysis and RAD51 functional detection are prospectively feasible in prediction of PARPi response.Keywords
Funding Information
- National Natural Science Foundation of China (81874107, 81572554, 81806203)
- Natural Science Foundation of Shandong Province (ZR2017BH008)
- China Postdoctoral Science Foundation (2019M652402)
This publication has 48 references indexed in Scilit:
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment OutcomeClinical Cancer Research, 2012
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2011
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Germline mutations in RAD51D confer susceptibility to ovarian cancerNature Genetics, 2011
- HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agentsOncogene, 2011
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsAnnals of Oncology, 2010
- Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian CancerJournal of Clinical Oncology, 2010
- DEGseq: an R package for identifying differentially expressed genes from RNA-seq dataBioinformatics, 2009
- Suppression of Nonhomologous End Joining Repair by Overexpression of HMGA2Cancer Research, 2009
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003